In another phase I trial (PCD4989), TNBC patients who received atezolizumab showed that the BLIA and LAR subtypes were associated with higher tumor-infiltrating immune cells such as TILs, PD-L1, and CD8-expressing immune cells compared to M and BLIS subtypes. This evidence concerns the gene CD274 and neoplasm.